Joel Lewis Sells 18,571 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CEO Joel Lewis sold 18,571 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $4.20, for a total value of $77,998.20. Following the completion of the transaction, the chief executive officer directly owned 898,021 shares of the company’s stock, valued at $3,771,688.20. This trade represents a 2.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Joel Lewis also recently made the following trade(s):

• On Tuesday, January 6th, Joel Lewis sold 37,698 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.58, for a total value of $134,958.84.
• On Monday, January 5th, Joel Lewis sold 27,731 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.91, for a total value of $108,428.21.
• On Wednesday, December 17th, Joel Lewis sold 7,829 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $55,272.74.
• On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.00, for a total transaction of $1,200.00.
• On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.07, for a total transaction of $87,529.40.
• On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.01, for a total transaction of $7,813.00.

Galectin Therapeutics Trading Up 2.6%

GALT stock opened at $3.54 on Thursday. The firm’s 50-day moving average is $5.27 and its two-hundred day moving average is $4.39. The company has a market capitalization of $228.23 million, a price-to-earnings ratio of -6.00 and a beta of 1.03. Galectin Therapeutics Inc. has a 52 week low of $1.07 and a 52 week high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities research analysts predict that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Institutional Investors Weigh In On Galectin Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wealthspire Advisors LLC lifted its holdings in shares of Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock valued at $1,012,000 after purchasing an additional 81,144 shares during the last quarter. Truist Financial Corp purchased a new position in Galectin Therapeutics in the 2nd quarter worth about $143,000. Geneos Wealth Management Inc. raised its holdings in Galectin Therapeutics by 8.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock worth $516,000 after buying an additional 34,300 shares during the period. Stratos Wealth Partners LTD. raised its holdings in Galectin Therapeutics by 17.8% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 60,750 shares of the company’s stock worth $128,000 after buying an additional 9,200 shares during the period. Finally, Nuveen LLC purchased a new stake in Galectin Therapeutics during the first quarter valued at about $34,000. 11.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright upped their price target on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Galectin Therapeutics has a consensus rating of “Hold” and an average price target of $11.00.

Galectin Therapeutics News Summary

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target and reiterated a “buy” on GALT in mid‑December, supporting upside sentiment and providing a bullish research anchor for the stock. MarketBeat – Analyst Note
• Neutral Sentiment: Institutional activity: small/new positions were reported from several funds (Nuveen, Atwood & Palmer, Hudson Bay, etc.) and Bank of America increased its stake; institutional ownership remains low (~11.7%) so impact is limited but worth monitoring. MarketBeat – Institutional Holdings
• Negative Sentiment: Regulatory / litigation risk: The Schall Law Firm and Pomerantz LLP announced investigations into Galectin that allege potential securities law violations; such probes typically increase legal risk and can pressure the stock until clarified. Schall Law Firm Investigation
• Negative Sentiment: Large, clustered insider selling: CEO Joel Lewis, CFO Jack Callicutt and insider Khurram Jamil sold sizable blocks across Jan. 2–6 (multiple Form 4s), trimming their ownership and raising concerns about insider sentiment or liquidity needs. Multiple filings may weigh on investor confidence. Form 4 – Joel Lewis
• Negative Sentiment: Insider sale summaries: CFO and other insiders sold tens of thousands of shares at prices between about $3.58–$4.20 in the same window; repeated insider sales amplify downside risk until rationale (e.g., diversification or personal liquidity) is disclosed. InsiderTrades – Sales Summary

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.